FAKHRAVAC
Sign in to saveFAKHRAVAC () is a COVID-19 vaccine developed in Iran by the Organization of Defensive Innovation and Research, a subsidiary of Iran's Ministry of Defense. It is the third Iranian COVID-19 vaccine reaching clinical trials. It is currently in phase III. It received emergency use authorization in Iran on 9 September 2021.
~2 min read
Encyclopedic overview
7 sectionsContents
- Medical uses
- Pharmacology
- Manufacturing
- Clinical trials
- Authorizations
- See also
- References
FAKHRAVAC () is a COVID-19 vaccine developed in Iran by the Organization of Defensive Innovation and Research, a subsidiary of Iran's Ministry of Defense. It is the third Iranian COVID-19 vaccine reaching clinical trials. It is currently in phase III. It received emergency use authorization in Iran on 9 September 2021.
The vaccine is named after the Iranian nuclear scientist Mohsen Fakhrizadeh. According to the Iranian authorities, he was working on a vaccine in response to the COVID-19 pandemic in Iran. Fakhrizadeh was assassinated in November 2020 in an attack Iran and US intelligence attributed to Israel.
Excerpted from Wikipedia’s “FAKHRAVAC” article, available under the CC BY-SA 4.0 licence.